87 results
DEFA14A
VERV
Verve Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
7:56am
of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. 3.Approval, on an advisory basis
8-K
VERV
Verve Therapeutics Inc
2 Apr 24
Other Events
7:13am
, in consultation with the study’s independent data and safety monitoring board, has decided to pause enrollment in the Heart-1 trial. Verve is conducting
S-8
EX-23.2
VERV
Verve Therapeutics Inc
27 Feb 24
Registration of securities for employees
8:32am
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement
S-8
VERV
Verve Therapeutics Inc
27 Feb 24
Registration of securities for employees
8:32am
in Exhibit 5.1).
Consent of Ernst and Young LLP, independent registered public accounting firm.
Power of attorney (included on the signature pages
S-8
EX-99.3
7ubktaj
27 Feb 24
Registration of securities for employees
8:32am
8-K
EX-99.1
igzhiul18p0a8ry
27 Feb 24
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
8-K
EX-1.1
6p0dswx8lw8
29 Nov 23
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
4:54pm
424B5
9g50sb pj79x2kew95
29 Nov 23
Prospectus supplement for primary offering
4:47pm
424B5
4zcpo92c
28 Nov 23
Prospectus supplement for primary offering
4:25pm
8-K
wy8lz0zwum 9x9or8
13 Nov 23
Other Events
6:34am